agilon health (AGL) Scheduled to Post Quarterly Earnings on Thursday

agilon health (NYSE:AGL) will release its earnings data after the market closes on Thursday, November 7th. Analysts expect agilon health to post earnings of ($0.10) per share for the quarter. agilon health has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

agilon health (NYSE:AGL) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.56 billion. agilon health had a negative return on equity of 29.91% and a negative net margin of 5.57%. The firm’s revenue was up 38.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.04) EPS. On average, analysts expect agilon health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

agilon health Stock Performance

Shares of AGL stock opened at $2.46 on Thursday. The firm has a 50 day moving average of $3.50 and a 200-day moving average of $5.09. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -3.37 and a beta of 0.54. The company has a quick ratio of 1.36, a current ratio of 1.36 and a debt-to-equity ratio of 0.04. agilon health has a 52 week low of $2.36 and a 52 week high of $18.37.

Insider Buying and Selling

In other news, CEO Steven Sell bought 20,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $3.36 per share, with a total value of $67,200.00. Following the transaction, the chief executive officer now directly owns 67,590 shares in the company, valued at $227,102.40. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $8.00 price objective on shares of agilon health in a report on Wednesday, August 7th. Citigroup reaffirmed a “sell” rating and set a $2.50 price target (down from $7.00) on shares of agilon health in a research note on Tuesday. Benchmark reissued a “buy” rating and issued a $9.00 price objective on shares of agilon health in a research note on Thursday, August 8th. Evercore ISI decreased their price objective on agilon health from $7.00 to $4.00 and set an “in-line” rating for the company in a report on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on agilon health from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, August 9th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, agilon health presently has a consensus rating of “Hold” and an average target price of $7.81.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.